重组水蛭素-2脂质体的制备及大鼠鼻腔给药药代动力学Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats
张玉杰;王筱亮;吴建梅;陈明霞;
摘要(Abstract)：
目的:为了提高重组水蛭素-2(rHV2)鼻腔给药的生物利用度,研制rHV2脂质体并对其理化性质和大鼠经鼻给药后药代动力学特点进行研究。方法:以逆相蒸发法制备rHV2脂质体;通过研究rHV2脂质体的包封率、粒径、稳定性来考察其理化性质;将制备的rHV2脂质体鼻腔给予大鼠,用呈色肽法测定不同时间血浆中rHV2的浓度,通过3p87程序拟合药代动力学参数。结果:用该法制备的脂质体包封率约为76.95%,平均粒径为168.3nm,分布在24~286 nm,相对峰宽±0.47,稳定性较好;药代动力学研究表明,rHV2脂质体较rHV2生理盐水溶液的鼻腔吸收明显增加。结论:将rHV2制备成脂质体可明显增加鼻腔给药的生物利用度。
关键词(KeyWords)： 重组水蛭素-2(rHV2);脂质体;鼻腔给药;药代动力学
基金项目(Foundation):
作者(Author): 张玉杰;王筱亮;吴建梅;陈明霞;
Email:
参考文献(References)：
- [1]Talley J D.Cardiology commentary and update:Hirudin[J].JArkansas Med Society,1995,91:445.
- [2]Markwarkt F,Kaiser B,Nowak G.Studies on antithromboticeffects of recombinant hirudin[J].Thromb Res,1989,54:377.
- [3]Markwardt F.The development of hirudin as an antithromboticdrug[J].Thromb Res,1994,74(1):1.
- [4]Illum L.Nasal drug delvery-possibilities,problems and solutions[J].J Contr Rel,2003,87:187.
- [5]Vyas S P,Goswami S K,Singh R.Liposomes based nasal deliverysystem of nifedipine:development and characterization[J].Int JPharm,1995,118(1):23.
- [6]董泽民.赖氨匹林鼻腔给药的研究[J].中国医药工业杂志,1995,26(5):199.
- [7]Griebach U,Sturzebecher C,Markwardt F.Assay of hirudin inplasma using a chromogenic thrombin substrate[J].Thromb Res,1985,37:347.
- [8]Chandler S G,Illum L,Tomas N M.Nasal absorption in rats.Ⅱ.Effect of enhancers on insulin absorption and nasal histology[J].Int J Pharm,1991,76:61.